Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) Overview 7 Therapeutics Development 8 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Products under Development by Stage of Development 8 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Products under Development by Therapy Area 9 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Products under Development by Indication 10 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Products under Development by Companies 14 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Products under Development by Universities/Institutes 16 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Companies Involved in Therapeutics Development 24 ChemoCentryx, Inc. 24 Dompe Farmaceutici S.p.A. 25 GlaxoSmithKline Plc 26 Novartis AG 27 Syntrix Biosystems, Inc. 28 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Drug Profiles 29 danirixin - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 DF-2755A - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 ladarixin - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 PAC-G31P - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 reparixin - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 SX-517 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 SX-576 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 SX-682 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Dormant Projects 43 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Discontinued Products 45 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Featured News & Press Releases 46 Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells 46 Oct 01, 2014: Dompe commitment in oncology against cancer stem cells 47 Sep 25, 2013: Pharmaceutical company Dompé launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation 47 Jul 10, 2013: Dompé announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true 49 Dec 06, 2012: Dompé Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium 49 Oct 23, 2012: Dompé Announces Enrollment Of First Patient In Phase III Trial On Reparixin 51 Oct 24, 2011: Dompé Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress 52 Oct 13, 2011: Dompé's Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation 53 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56

List of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Assessment by Monotherapy/Combination Products, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by ChemoCentryx, Inc., H1 2016 24 Pipeline by Dompe Farmaceutici S.p.A., H1 2016 25 Pipeline by GlaxoSmithKline Plc, H1 2016 26 Pipeline by Novartis AG, H1 2016 27 Pipeline by Syntrix Biosystems, Inc., H1 2016 28 Dormant Projects, H1 2016 43 Dormant Projects (Contd..1), H1 2016 44 Discontinued Products, H1 2016 45 List of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 18 Number of Products by Stage and Mechanism of Actions, H1 2016 19 Number of Products by Routes of Administration, H1 2016 20 Number of Products by Stage and Routes of Administration, H1 2016 20 Number of Products by Molecule Types, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 22

ChemoCentryx, Inc. Dompe Farmaceutici S.p.A. GlaxoSmithKline Plc Novartis AG Syntrix Biosystems, Inc.